Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Engineering Infectious cDNAs of Coronavirus as Bacterial Artificial Chromosomes

  • Almazán, Fernando
  • Márquez-Jurado, Silvia
  • Nogales, Aitor
  • Enjuanes Sánchez, Luis
The large size of the coronavirus (CoV) genome (around 30 kb) and the instability in bacteria of plasmids carrying CoV replicase sequences, represent serious restrictions for the development of CoV infectious clones using reverse genetic systems similar to those used for smaller positive sense RNA viruses. To overcome these problems, several approaches have been established in the last thirteen years. Here we describe the engineering of CoV full-length cDNA clones as bacterial artificial chromosomes (BACs), using the Middle East respiratory syndrome CoV (MERS-CoV) as a model., This work was supported by grants from the Ministry of Science and Innovation of Spain (MCINN) (BIO2010-16705), the European Community's Seventh Framework Programme (FP7/2007-2013) under the project “EMPERIE” (HEALTH-F3-2009-223498), and the National Institute of Health (NIH) of USA (2P01AI060699-06A1). S. M. received a predoctoral fellowship from the National Institute of Health (ISCIII) of Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Recombinant live vaccines to protect against the severe acute respiratory syndrome coronavirus

  • Enjuanes Sánchez, Luis
  • Nieto-Torres, José L.
  • Jiménez-Guardeño, José Manuel
  • DeDiego, Marta L.
The severe acute respiratory syndrome (SARS) coronavirus (CoV) was identified as the etiological agent of an acute respiratory disease causing atypical pneumonia and diarrhea with high mortality. Different types of SARS-CoV vaccines, including nonreplicative and vectored vaccines, have been developed. Administration of these vaccines to animal model systems has shown promise for the generation of efficacious and safe vaccines. Nevertheless, the identification of side effects, preferentially in the elderly animal models, indicates the need to develop novel vaccines that should be tested in improved animal model systems. Live attenuated viruses have generally proven to be the most effective vaccines against viral infections. A limited number of SARS-CoV attenuating modifications have been described, including mutations, and partial or complete gene deletions affecting the replicase, like the nonstructural proteins (nsp1 or nsp2), or the structural genes, and drastic changes in the sequences that regulate the expression of viral subgenomic mRNAs. A promising vaccine candidate developed in our laboratory was based on deletion of the envelope E gene alone, or in combination with the removal of six additional genes nonessential for virus replication. Viruses lacking E protein were attenuated, grew in the lung, and provided homologous and heterologous protection. Improvements of this vaccine candidate have been directed toward increasing virus titers using the power of viruses with mutator phenotypes, while maintaining the attenuated phenotype. The safety of the live SARS-CoV vaccines is being increased by the insertion of complementary modifications in genes nsp1, nsp2, and 3a, by gene scrambling to prevent the rescue of a virulent phenotype by recombination or remodeling of vaccine genomes based on codon deoptimization using synthetic biology. The newly generated vaccinecandidates are very promising, but need to be evaluated in animal model systems that include young and aged animals., This work was supported by grants from the Comisión Interministerial de Ciencia y Tecnología (CICYT) Bio2007 – 60978, the Consejería de Educación y Cultura de la Comunidad de Madrid S-SAL-0185/06, Ministerio de Ciencia e Innovación (MICINN) Project PROFIT, CIT-010000-2007-8, Fort Dodge Veterinaria, and the European Communities (Frame VII, EMPERIE project HEALTH-F3-2009-223498, and PLAPROVA project KBBE-2008-227056). MLD, JLN, and JMJ received fellowships from the Department of Education and Science of Spain. The work is also supported by a grant from the National Institutes of Health (US) RO1 AI079424-01A1, W000151845 (LE).